Filing summary
Issuer and period: The supplied filing is DelMar Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2013. This does not match the request metadata identifying Tuhura Biosciences, Inc.; verify the issuer before relying on this summary.
Business context and reporting period
DelMar was a development-stage cancer drug company with no product revenue. Its lead candidate, VAL-083, was being studied in a Phase I/II trial for recurrent glioblastoma. The January 2013 reverse acquisition made DelMar (BC) the accounting acquirer. All financial amounts below are U.S. dollars.
Financial results and liquidity
| Metric | Three months ended June 30, 2013 | Six months ended June 30, 2013 | Comparable 2012 period |
|---|---|---|---|
| Revenue | No product revenue reported | No product revenue reported | No product revenue reported |
| Research and development expense | $584,412 | $1,216,359 | $733,160 and $987,534, respectively |
| General and administrative expense | $1,654,380 | $2,574,757 | $394,792 and $562,583, respectively |
| Net loss | $6,813,626 | $14,218,945 | $1,137,726 and $1,549,261, respectively |
| Loss per share | $0.22 | $0.51 | $0.08 and $0.12, respectively |
| Cash used in operations | Not separately stated | $3,374,310 | $458,991 |
At June 30, cash and cash equivalents were $6,282,992, total assets $6,521,148, and reported working capital $5,853,459. Stockholders’ deficiency was $7,712,924. The balance sheet reported total liabilities of $14,234,072, including a $12,986,827 derivative liability. The $268,299 Valent loan, including accrued interest, was presented as non-current; it is unsecured, payable on demand, and bears 3% interest. No meaningful revenue or gross margin was reported.
Material changes and unusual items
- Net loss increased substantially year over year. The filing attributes much of the change to warrant-related derivative accounting, offering costs, share-based compensation, and higher administrative and professional expenses, rather than solely to operating activity.
- The derivative liability rose from $121,000 at December 31, 2012 to $12,986,827 at June 30, 2013. A $7,142,775 fair-value change was recorded in the six-month results; the filing’s narrative labels the change a “gain,” while the liability increase and presentation in the loss statement indicate a material accounting item requiring reconciliation.
- General and administrative expense included substantial share-based compensation and costs associated with the reverse acquisition, public-company reporting, and Form S-1 work. Management said some transaction and filing costs were one-time. Six-month R&D expense rose 23%; reported G&A expense rose 358%.
- The company raised $10.5 million gross in a 2013 unit offering, reporting approximately $8.575 million net proceeds after specified offering costs. It issued 13,125,002 units, each including a share and a five-year warrant, and issued 5,250,000 placement-agent warrants.
Outlook, risks, and contingencies
- Management estimated that available funding would support operations for at least 21 months, based on current estimates. It also said additional financing would be needed over the medium to longer term and was not assured on acceptable terms. Cost overruns, delays, or financing constraints could require reducing or delaying development programs.
- The company planned continued dose escalation in the VAL-083 Phase I/II trial; the maximum tolerated dose had not been reached in the cohorts described. Management reported interim observations of tolerability and some stable disease or tumor regression, but these were early, small-cohort findings, not established efficacy.
- VAL-083 was approved in China for chronic myelogenous leukemia and lung cancer, but had no approvals outside China. The company described a collaboration and supply arrangement with Guangxi Wuzhou Pharmaceuticals, and noted risks from comparatively weak intellectual-property protection in China. No payments had been made under that agreement as of the filing.
- Warrant and option dilution is significant: 24,985,009 warrants and 1,140,000 options were outstanding at June 30. Their inclusion was excluded from diluted loss per share as anti-dilutive. Subsequent to quarter-end, 200,000 placement-agent warrants were cashlessly exercised for 123,810 shares, 186,000 warrants were exercised for shares with no additional consideration, and 100,000 exchangeable shares converted into common shares.
- The filing reported no legal proceedings, no defaults upon senior securities, and no off-balance-sheet arrangements. Management stated disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for DelMar Pharmaceuticals, Inc., not Tuhura Biosciences, Inc.
- Reconcile the derivative-liability fair-value accounting and the filing’s inconsistent characterization of the $7.1 million change as a gain versus its impact on reported loss.
- Review warrant terms, registration status, potential dilution, and the effect of warrant valuation assumptions; the derivative liability uses Level 3 inputs.
- Assess the assumptions behind management’s estimate of at least 21 months of runway, given the six-month operating cash use and lack of product revenue.
- Verify clinical-trial progress and interpret interim VAL-083 observations cautiously; the reported cohorts were small and the filing provides no definitive efficacy conclusion.